NO20074311L - Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet - Google Patents
Kinazolinderivat med tyrosinkinase-inhiberendeaktivitetInfo
- Publication number
- NO20074311L NO20074311L NO20074311A NO20074311A NO20074311L NO 20074311 L NO20074311 L NO 20074311L NO 20074311 A NO20074311 A NO 20074311A NO 20074311 A NO20074311 A NO 20074311A NO 20074311 L NO20074311 L NO 20074311L
- Authority
- NO
- Norway
- Prior art keywords
- substituted
- alkyl group
- hydrogen atom
- tyrosine kinase
- inhibitory activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
En forbindelse representert ved den generelle formel (I) eller et farmasøytisk aksepterbart salt derav eller et solvat av forbindelsen eller saltet: (I) hvor Rx representerer en gruppe representert ved formel (II): hvor representerer et hydrogenatom, en alkylgmppe som kan være substituert eller lignende,. Z representerer -O-, -N(R)- eller lignende, Rrepresenterer et hydrogenatom, en alkylgruppe eller lignende, Rrepresenterer et hydrogenatom, en alkylgruppe som kan være substituert eller lignende, R representerer et hydrogenatom, en alkylgruppe som kan være substituert eller lignende, Rrepresenterer en alkylgruppe som kan være substituert eller lignende, Wrepresenterer en ikke-aromatisk nitrogenert heterocyklisk gruppe som kan være substituert, og Rrepresenterer et hydrogenatom, en alkylgruppe som kan være substituert eller lignende; Rog Rrepresenterer uavhengig et hydrogenatom, en alkylgruppe som kan være substituert eller lignende; X representerer -O-, -S-, -N(R)- eller lignende; R representerer et hydrogenatom, en alkylgruppe eller lignende; og A representerer en fenylgruppe som kan være substituert eller lignende. Forbindelsen kan inhibere både EGF reseptor-tyrosinkinase og HER2 tyrosinkinase.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005047383 | 2005-02-23 | ||
JP2005156828 | 2005-05-30 | ||
PCT/JP2006/303125 WO2006090717A1 (ja) | 2005-02-23 | 2006-02-22 | チロシンキナーゼ阻害作用を有するキナゾリン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20074311L true NO20074311L (no) | 2007-11-23 |
NO343403B1 NO343403B1 (no) | 2019-02-25 |
Family
ID=36927355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20074311A NO343403B1 (no) | 2005-02-23 | 2007-08-23 | Kinazolinderivat med tyrosinkinase-inhiberende aktivitet og farmasøytisk sammensetning |
Country Status (16)
Country | Link |
---|---|
US (2) | US8202879B2 (no) |
EP (1) | EP1854789B1 (no) |
JP (1) | JP4137174B2 (no) |
KR (1) | KR100910333B1 (no) |
CN (1) | CN101163684B (no) |
AU (1) | AU2006216266C1 (no) |
BR (1) | BRPI0606905B1 (no) |
CA (1) | CA2599328C (no) |
DK (1) | DK1854789T3 (no) |
ES (1) | ES2431843T3 (no) |
NO (1) | NO343403B1 (no) |
PL (1) | PL1854789T3 (no) |
PT (1) | PT1854789E (no) |
RU (1) | RU2414457C2 (no) |
TW (1) | TWI372147B (no) |
WO (1) | WO2006090717A1 (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1854789B1 (en) * | 2005-02-23 | 2013-10-09 | Shionogi & Co., Ltd. | Quinazoline derivative having tyrosine kinase inhibitory activity |
CN101003514A (zh) * | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
US7547781B2 (en) * | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
SG174774A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Quinazoline based egfr inhibitors containing a zinc binding moiety |
JP6087504B2 (ja) | 2008-11-07 | 2017-03-01 | マサチューセッツ インスティテュート オブ テクノロジー | アミノアルコールリピドイドおよびその使用 |
TWI466872B (zh) * | 2008-12-25 | 2015-01-01 | Shionogi & Co | 喹唑啉衍生物之製造方法 |
AU2012328570B2 (en) * | 2011-10-27 | 2017-08-31 | Massachusetts Institute Of Technology | Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof |
CN103288756B (zh) * | 2012-02-29 | 2016-04-20 | 江苏先声药物研究有限公司 | 一种喹唑啉中间体的甲醇溶剂合物及其制备方法 |
CN105407894A (zh) | 2013-03-14 | 2016-03-16 | 康威基内有限公司 | 用于抑制含布罗莫结构域的蛋白质的方法和组合物 |
WO2015182682A1 (ja) * | 2014-05-29 | 2015-12-03 | 塩野義製薬株式会社 | アルキニルケトン誘導体の製造方法 |
WO2017018476A1 (ja) * | 2015-07-29 | 2017-02-02 | 塩野義製薬株式会社 | キナゾリン誘導体の塩またはその結晶およびそれらの製造方法 |
EP3359526A4 (en) | 2015-10-05 | 2019-04-03 | The Trustees of Columbia University in the City of New York | ACTIVATORS OF AUTOPHAGIC FLOW AND PHOSPHOLIPASE D AND CLAIRANCE OF PROTEIN AGGREGATES COMPRISING TAU AND TREATMENT OF PROTEINEOPATHIES |
ES2918589T3 (es) | 2015-11-25 | 2022-07-19 | Convergene Llc | Inhibidores de bromodomios BET bicíclicos y usos de los mismos |
US20180030403A1 (en) | 2016-07-28 | 2018-02-01 | Bobban Subhadra | Devices, systems and methods for the production of humanized gut commensal microbiota |
JP7191446B2 (ja) * | 2017-01-30 | 2022-12-19 | 塩野義製薬株式会社 | キナゾリン誘導体を含有する固形製剤 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
EP2295415A1 (en) * | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
ES2186908T3 (es) * | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
AU763242B2 (en) | 1999-09-21 | 2003-07-17 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
DE60237145D1 (de) | 2001-02-21 | 2010-09-09 | Mitsubishi Tanabe Pharma Corp | Chinazolinderivate |
AU2002342051B2 (en) | 2001-10-12 | 2009-06-11 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
PL375974A1 (en) | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
WO2004069145A2 (en) | 2003-02-07 | 2004-08-19 | Dr. Reddy's Laboratories Ltd. | Anticancer compounds, process for their preparation and pharmaceutical compositions containing them |
JO2785B1 (en) | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
WO2005067667A2 (en) | 2004-01-07 | 2005-07-28 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
US8017321B2 (en) | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
EP1854789B1 (en) * | 2005-02-23 | 2013-10-09 | Shionogi & Co., Ltd. | Quinazoline derivative having tyrosine kinase inhibitory activity |
-
2006
- 2006-02-22 EP EP06714265.3A patent/EP1854789B1/en active Active
- 2006-02-22 CA CA2599328A patent/CA2599328C/en active Active
- 2006-02-22 CN CN2006800136753A patent/CN101163684B/zh active Active
- 2006-02-22 KR KR1020077019256A patent/KR100910333B1/ko active IP Right Grant
- 2006-02-22 BR BRPI0606905-3A patent/BRPI0606905B1/pt active IP Right Grant
- 2006-02-22 JP JP2007504734A patent/JP4137174B2/ja active Active
- 2006-02-22 RU RU2007135023/04A patent/RU2414457C2/ru active
- 2006-02-22 WO PCT/JP2006/303125 patent/WO2006090717A1/ja active Application Filing
- 2006-02-22 DK DK06714265.3T patent/DK1854789T3/da active
- 2006-02-22 ES ES06714265T patent/ES2431843T3/es active Active
- 2006-02-22 AU AU2006216266A patent/AU2006216266C1/en active Active
- 2006-02-22 PL PL06714265T patent/PL1854789T3/pl unknown
- 2006-02-22 US US11/884,819 patent/US8202879B2/en active Active
- 2006-02-22 PT PT67142653T patent/PT1854789E/pt unknown
- 2006-02-23 TW TW095106013A patent/TWI372147B/zh active
-
2007
- 2007-08-23 NO NO20074311A patent/NO343403B1/no unknown
-
2012
- 2012-01-26 US US13/359,326 patent/US8349857B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PL1854789T3 (pl) | 2014-03-31 |
AU2006216266C1 (en) | 2010-08-26 |
TWI372147B (en) | 2012-09-11 |
DK1854789T3 (da) | 2013-10-21 |
EP1854789A4 (en) | 2009-06-17 |
US8349857B2 (en) | 2013-01-08 |
BRPI0606905B1 (pt) | 2021-06-01 |
JPWO2006090717A1 (ja) | 2008-07-24 |
WO2006090717A1 (ja) | 2006-08-31 |
AU2006216266B2 (en) | 2010-02-18 |
CA2599328C (en) | 2012-04-17 |
BRPI0606905A2 (pt) | 2009-07-28 |
US8202879B2 (en) | 2012-06-19 |
PT1854789E (pt) | 2013-10-23 |
JP4137174B2 (ja) | 2008-08-20 |
EP1854789B1 (en) | 2013-10-09 |
CN101163684A (zh) | 2008-04-16 |
NO343403B1 (no) | 2019-02-25 |
US20120123114A1 (en) | 2012-05-17 |
ES2431843T3 (es) | 2013-11-28 |
EP1854789A1 (en) | 2007-11-14 |
AU2006216266A8 (en) | 2009-04-02 |
CN101163684B (zh) | 2012-08-29 |
RU2007135023A (ru) | 2009-03-27 |
KR20070098941A (ko) | 2007-10-05 |
US20090143414A1 (en) | 2009-06-04 |
AU2006216266A2 (en) | 2006-08-31 |
CA2599328A1 (en) | 2006-08-31 |
KR100910333B1 (ko) | 2009-07-31 |
RU2414457C2 (ru) | 2011-03-20 |
TW200640880A (en) | 2006-12-01 |
AU2006216266A1 (en) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20074311L (no) | Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet | |
WO2005110410A3 (en) | Kinase inhibitors as therapeutic agents | |
NO20073956L (no) | Pyrazolderivater for inhibering av CDK og GSK | |
WO2005074603A3 (en) | Aminobenzoxazoles as therapeutic agents | |
NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
TW200618800A (en) | Heterocyclic compounds | |
EA200801381A1 (ru) | Производные пиримидина | |
TN2010000052A1 (fr) | Derives de pyrazole et leur utilisation comme inhibiteurs de raf | |
WO2007016392A3 (en) | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
NO20082482L (no) | Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer | |
NO20073926L (no) | Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser | |
NO20070532L (no) | Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer | |
NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
TNSN08089A1 (en) | Substituted benzimidazoles and methods of preparation | |
ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
NO20062185L (no) | Hepatitt C virus-inhibitorer | |
WO2008060476A3 (en) | Nitrogen-containing heterocyclic compounds and methods of use thereof | |
NO20083923L (no) | Pyrazolkinoloner er potente parp-inhibitorer | |
NO20084583L (no) | Makrosykliske kinase-inhibitorer | |
DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
TW200637539A (en) | CTGF inhibitors | |
NO20063647L (no) | Nye inhibitorer av chymase | |
NO20065327L (no) | Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid. | |
WO2009069736A1 (ja) | 含窒素化合物 |